Insider · CIK 0001218702
D Keith Grossman
director
Files at NVRO (NEVRO CORP), OM (Outset Medical, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 2, 2025 | OM Outset Medical, Inc. | AGrant or award Common Stock | +8,983 | $0.00 | $0 | 13,918 | Jun 4, 2025 |
| Apr 3, 2025 | NVRO NEVRO CORP | DDisposition to issuer Common Stock | -228,552 | - | - | 0 | Apr 3, 2025 |
| Mar 11, 2025 | NVRO NEVRO CORP | FTax withholding Common Stock | -1,641 | $5.78 | $9,485 | 228,552 | Mar 11, 2025 |
| Mar 10, 2025 | OM Outset Medical, Inc. | MOption exercise Common Stockindirect: Grossman Fam Trust | +187,500 | - | - | 192,686 | Mar 11, 2025 |
| Mar 7, 2025 | OM Outset Medical, Inc. | AGrant or award Series A Non-Voting Convertible Preferredderivativeindirect: Grossman Fam Trust | +750 | $200.00 | $150k | 750 | Mar 11, 2025 |
| Mar 10, 2025 | OM Outset Medical, Inc. | MOption exercise Series A Non-Voting Convertible Preferredderivativeindirect: Grossman Fam Trust | -750 | $0.00 | $0 | 0 | Mar 11, 2025 |
| Feb 28, 2025 | NVRO NEVRO CORP | AGrant or award Common Stock | +4,750 | $0.00 | $0 | 232,281 | Mar 4, 2025 |
| Feb 28, 2025 | NVRO NEVRO CORP | FTax withholding Common Stock | -1,071 | $5.72 | $6,126 | 231,210 | Mar 4, 2025 |
| Mar 3, 2025 | NVRO NEVRO CORP | FTax withholding Common Stock | -1,017 | $5.72 | $5,817 | 230,193 | Mar 4, 2025 |
| Dec 3, 2024 | NVRO NEVRO CORP | FTax withholding Common Stock | -928 | $4.26 | $3,953 | 227,531 | Dec 4, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.